BWP
OCUL icon

Balboa Wealth Partners’s Ocular Therapeutix OCUL Stock Holding History

Balboa Wealth Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-38,000
Closed -$346K – 331
2024
Q1 		$346K Buy
+38,000
New +$270K 0.1% 150

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Balboa Wealth Partners's OCUL Position: Q2 2024 in Review

Balboa Wealth Partners sold out of Ocular Therapeutix (OCUL) in Q2 2024, closing a stake of 38,000 shares — an estimated $346K sold.

Balboa Wealth Partners first reported a position in OCUL in Q1 2024 and held it in 1 quarter. The position peaked at $346K in Q1 2024. 150 funds tracked by Wall St. Rank hold OCUL as of Q2 2024.

  • Balboa Wealth Partners reported no remaining Ocular Therapeutix position as of Q2 2024 after selling out during the quarter.
  • Balboa Wealth Partners sold 38,000 Ocular Therapeutix shares in Q2 2024, an estimated $346K.
  • Balboa Wealth Partners first reported a position in Ocular Therapeutix in Q1 2024 and held it in 1 quarter.
  • Balboa Wealth Partners's Ocular Therapeutix position peaked at $346K in Q1 2024.
  • 150 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2024.

Based on Balboa Wealth Partners's 13F filing for Q2 2024, filed 13 Aug 2024.